<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liraglutide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liraglutide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Liraglutide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12243" href="/d/html/12243.html" rel="external">see "Liraglutide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121884" href="/d/html/121884.html" rel="external">see "Liraglutide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F59011466"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Glucagon-Like Peptide-1 Receptor Agonists Safety Update</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Fupdate-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type&amp;token=miTanb%2Bz8Mpo90N4aa9rnBvzPyMcyGMouSYn352zIq27XyRAnm%2BDWunTXNDIRGRVPdvEcJ4t0dBZwKHPsWODdcKNBqg8p81GHTpH2D6qQhfyYSllM0BIXdmigC6Atf7BXgPxeZTU1rPJai25j9dr%2BiXxmVJc5lhSTyKtYrSUSj8%3D&amp;TOPIC_ID=9522" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F9844180"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thyroid C-cell tumor risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Liraglutide causes dose-dependent and treatment duration–dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.</p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of liraglutide and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with liraglutide.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9832447"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Saxenda;</li>
<li>Victoza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871143"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Saxenda;</li>
<li>Victoza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9844226"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F9844261"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cli</b>
<b>nical considerations: </b> May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease, when weight loss is desired, and/or in patients with an HbA<sub>1c</sub> relatively far from goal (eg, HbA<sub>1c</sub> 9% to 10%) and type 1 diabetes is not likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-27295427','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-27295427','lexi-content-ref-Wexler.1'])">Ref</a></span>). Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106','lexi-content-ref-27709794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106','lexi-content-ref-27709794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily; if optimal glycemic response is not achieved after an additional week of treatment, may increase further to 1.8 mg once daily. <b>Note:</b> The lower initial dose (0.6 mg daily) is intended to reduce GI symptoms; it does not provide effective glycemic control.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunct to diet and exercise in patients with a BMI ≥30 kg/m<sup>2</sup> or patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, hypertension, dyslipidemia). Considered a preferred pharmacologic weight-loss option in patients with a BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes mellitus, particularly in those with atherosclerotic cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27219496','lexi-content-ref-36273831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27219496','lexi-content-ref-36273831'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 0.6 mg once daily for 1 week; increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily. If the patient cannot tolerate an increased dose during dose escalation, consider delaying dose escalation for 1 additional week. Patients may continue on the maximum tolerated dose (even if &lt;3 mg/day) if goal weight loss is achieved on that dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36273831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36273831'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Evaluate change in body weight after 12 weeks at maximum tolerated dose or 16 weeks after initiation of therapy; discontinue if at least 4% to 5% of baseline body weight loss has not been achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Missed doses:</b> In the event of a missed dose, the once-daily regimen can be resumed with the next scheduled dose (an extra dose or an increase in the next dose should <b>not</b> be attempted); if &gt;3 days have passed since the last liraglutide dose, reinitiate therapy at 0.6 mg/day to avoid GI symptoms and titrate according to clinical judgment considering previous GI tolerability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991079"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20002084','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20002084','lexi-content-ref-manu.1'])">Ref</a></span>). Use with caution in severe impairment; limited data are available in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30566006','lexi-content-ref-32132141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30566006','lexi-content-ref-32132141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25526642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25526642'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); use with caution due to limited clinical evidence. One small, short-term study demonstrated efficacy in patients with type 2 diabetes receiving hemodialysis, although liraglutide steady-state trough concentrations were ~49% higher and increased rates of nausea and vomiting (self limited, usually during initiation and dose increases) were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26283739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26283739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.1'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20002084','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20002084','lexi-content-ref-manu.1'])">Ref</a></span>); use with caution due to limited clinical evidence. One small, retrospective study suggests efficacy and safety of once-daily 0.6 to 0.9 mg doses of liraglutide in patients with type 2 diabetes receiving peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26556397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26556397'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988360"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; use with caution due to limited experience.</p></div>
<div class="block doe drugH1Div" id="F9844262"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53339025"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121884" href="/d/html/121884.html" rel="external">see "Liraglutide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7253bb59-b685-4f43-aa48-4aa83f602807">Diabetes mellitus, type 2; adjunct to diet and exercise</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2; adjunct to diet and exercise: Note: </b>Glucagon-like peptide-1 (GLP-1) receptor agonists may be considered an additional therapeutic option in pediatric patients with type 2 diabetes mellitus who are ≥3 months post diagnosis with an HbA<sub>1c</sub> of ≥7% while on metformin therapy (maximized) in addition to a healthy lifestyle (eg, diet, exercise) with or without insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36161685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36161685'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Victoza: SUBQ: Initial: 0.6 mg once daily for at least 1 week; may increase by 0.6 mg/day increments at weekly intervals to achieve glycemic control (week 2: increase to 1.2 mg once daily; week 3: increase to 1.8 mg once daily); maximum daily dose: 1.8 mg/<b>day</b>. In clinical trials, all patients were on concomitant stable doses of metformin (1,000 to 2,000 mg/day) with or without basal insulin; patients on basal insulin had insulin dose reductions (by 20%) during liraglutide therapy titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses:</i> If more than 3 days of therapy are missed, therapy should be restarted at the initial dose (0.6 mg/day) and retitrated to avoid GI symptoms.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="160a93e9-ffb8-4485-88ca-8b2d81537ab1">Weight management, chronic; adjunct to strict lifestyle interventions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic; adjunct to strict lifestyle interventions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Saxenda: SUBQ: Initial: 0.6 mg once daily for 1 week; increase as tolerated by 0.6 mg/day increments at weekly intervals to a target dose of 3 mg once daily. If the patient cannot tolerate an increased dose during dose escalation, consider lowering dose to the previous level. If the 3 mg target daily dose is not tolerated, reduce dose to 2.4 mg daily; discontinue if the 2.4 mg dose is not tolerated. After 12 weeks on the maintenance dose, assess BMI; if patient has not had a reduction ≥1% from baseline, discontinue therapy since patient is unlikely to achieve meaningful and sustainable results with liraglutide.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53339026"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to severe impairment:</i> No dosage adjustment necessary; use with caution, particularly when initiating therapy and with dose escalation; there is limited data in this population. Acute renal failure and worsening of chronic kidney disease (may require hemodialysis) has been reported; provide supportive care and consider discontinuation of liraglutide or other causative agents as necessary. <b>Note:</b> Some experts do not recommend use for weight loss in patients with severe renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30677262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30677262'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>End-stage kidney disease (ESKD):</i> No dosage adjustment necessary; use with caution when initiating therapy and with dose escalation; there are limited data in this population. Acute renal failure and worsening of chronic kidney disease (may require hemodialysis) has been reported; provide supportive care and consider discontinuation of liraglutide or other causative agents as necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25526642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25526642'])">Ref</a></span>); there are no dosage adjustments provided in the manufacturer's labeling; use with caution due to limited clinical evidence in patients with ESKD. <b>Note: </b>Some experts do not recommend use for weight loss in patients with ESKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30677262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30677262'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not likely dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.1'])">Ref</a></span>); there are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F53339050"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: SUBQ: Mild to severe impairment: No dosage adjustment necessary; use with caution due to limited experience.</p></div>
<div class="block arsc drugH1Div" id="F54814735"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute kidney injury (AKI), including <b>acute interstitial nephritis </b>and <b>acute tubular necrosis </b>which sometimes require dialysis, has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24315766','lexi-content-ref-22392833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24315766','lexi-content-ref-22392833'])">Ref</a></span>). According to the manufacturer, altered kidney function has been reversed following discontinuation of liraglutide and initiation of supportive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; exact mechanism is unknown. Prerenal AKI may occur due to dehydration and volume contraction secondary to GI symptoms (eg, nausea, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22392833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22392833'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on GI symptoms, initiation or dosage adjustment of concomitant medications, and/or comorbid conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume contraction (eg, during periods of severe vomiting or diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gallbladder disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallbladder disease </b>and<b></b>
<b>biliary tract disease</b>, including <b>cholelithiasis</b>, <b>cholecystitis</b>, and <b>cholangitis</b> have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide; some have required hospitalization or <b>cholecystectomy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939'])">Ref</a></span>). Resolution of biliary stones following discontinuation has been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); not fully understood. Animal studies and in vitro data have demonstrated that glucagon-like peptide 1 enhances the proliferation and functional activity of cholangiocytes, which may result in gallbladder diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17631146','lexi-content-ref-18829977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17631146','lexi-content-ref-18829977'])">Ref</a></span>). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31399438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31399438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset has occurred as quickly as 4 to 8 weeks and as long as &gt;1 year following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001','lexi-content-ref-25725635','lexi-content-ref-26132939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001','lexi-content-ref-25725635','lexi-content-ref-26132939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (eg, &gt;26 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who experience above-average weight loss with liraglutide treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26132939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26132939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects are the most common adverse reactions associated with glucagon-like peptide 1 receptor agonists, mainly <b>diarrhea</b>, <b>nausea</b>, and <b>vomiting</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27981757','lexi-content-ref-25375397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27981757','lexi-content-ref-25375397'])">Ref</a></span>). <b>Constipation, dyspepsia,</b> and <b>abdominal pain </b>may also occur. GI effects tend to decrease over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation of centers involved in appetite regulation, satiety, and nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; generally greater with higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid titration</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, immediate hypersensitivity reactions, including <b>anaphylaxis</b> and <b>angioedema</b>, have been reported with glucagon-like peptide 1 (GLP-1) receptor agonists, including liraglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642'])">Ref</a></span>). Exendin-based GLP-1 receptor agonists (eg, exenatide, lixisenatide) are associated with a doubling of reporting odds of anaphylactic reaction, compared with human-analogue GLP-1 receptor agonists (eg, liraglutide, dulaglutide, semaglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31806579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31806579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions, such as <b>psoriasiform eruption</b> (either generalized or at the site of the injection), <b>pustular rash</b> (photodistributed exanthematous pustulosis), and <b>vesicular eruption </b>(vesiculopustular dermatosis) have been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22727533','lexi-content-ref-31903972','lexi-content-ref-32301438','lexi-content-ref-31389984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22727533','lexi-content-ref-31903972','lexi-content-ref-32301438','lexi-content-ref-31389984'])">Ref</a></span>). Time to resolution is variable occurring 2 weeks to up to 5 months after discontinuation of liraglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31903972','lexi-content-ref-32301438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31903972','lexi-content-ref-32301438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Formation of neutralizing antibodies to liraglutide has no apparent effect on efficacy or safety, including hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21450987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21450987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-31296642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Varied; may occur from 1 day after initiation of liraglutide to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22727533','lexi-content-ref-31389984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22727533','lexi-content-ref-31389984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between GLP-1 receptor agonists is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014'])">Ref</a></span>); until further studies are available, liraglutide should be used with caution in patients with a history of anaphylaxis or angioedema to other GLP-1 receptor agonists. Skin tests have been used in patients with histories of immediate hypersensitivity reactions to GLP-1 receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31296642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Medullary thyroid carcinoma</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with liraglutide. It is unknown whether liraglutide causes thyroid C-cell tumors in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. According to the manufacturer, human cases of <b>medullary thyroid carcinoma </b>(MTC) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown. Animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of liraglutide may be rodent-specific. Humans have far fewer C-cells than rodents, and expression of the glucagon-like peptide 1 receptor in human C-cells is very low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20203154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20203154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 may be at an increased risk</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute pancreatitis</b> (including <b>hemorrhagic pancreatitis</b> and <b>necrotizing pancreatitis</b> with some fatalities), chronic<b> pancreatitis</b>, and <b>pancreatic adenocarcinoma</b> have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Causality has not been firmly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24571751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24571751'])">Ref</a></span>). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells, which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27883260','lexi-content-ref-25633664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27883260','lexi-content-ref-25633664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Not well characterized.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F9844235"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Obesity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Increased heart rate (&gt;10 bpm from baseline: 34%; &gt;20 bpm from baseline: 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypoglycemia (monotherapy without type 2 diabetes: adolescents: 15%, adults: 2%; monotherapy with type 2 diabetes: adults: 13%; combination therapy with sulfonylurea: adults: 28%; severe hypoglycemia [requiring the assistance of another person] in combination therapy: adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (adolescents: 5%; adults: 19%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Constipation (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-constipation-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-constipation-obesity')">table 1</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Constipation (Obesity)</span>, diarrhea (adolescents and adults: 21% to 22%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Diarrhea (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-diarrhea-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-diarrhea-obesity')">table 2</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Diarrhea (Obesity)</span>, gastroenteritis (adolescents and adults: 5% to 13%), nausea (adolescents and adults: 39% to 42%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Nausea (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-nausea-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-nausea-obesity')">table 3</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Nausea (Obesity)</span>, vomiting (adolescents: 34%; adults: 16%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Vomiting (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-vomiting-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-vomiting-obesity')">table 4</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Vomiting (Obesity)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Constipation (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-constipation-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Constipation (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Diarrhea (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-diarrhea-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Diarrhea (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Nausea (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-nausea-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Nausea (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Vomiting (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-vomiting-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Vomiting (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Antibody development (adolescents: 12%; adults: 3%; neutralizing: adults: 1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site reaction (including erythema at injection site, injection site pruritus, rash at injection site) (1% to 14%) (Carvallo 2020; Neel 2019)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Circulatory shock (≤1%), hypotension (≤1%), orthostatic hypotension (≤1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Altered hormone level (1%; increased serum calcitonin), dyslipidemia (adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distension (5%), abdominal distress (adolescents: 5%), abdominal pain (adults: 5%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Abdominal Pain (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-abdominal-pain-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-abdominal-pain-obesity')">table 5</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Abdominal Pain (Obesity)</span>, cholelithiasis (2%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Cholelithiasis (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-cholelithiasis-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-cholelithiasis-obesity')">table 6</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Cholelithiasis (Obesity)</span>, dyspepsia (adolescents and adults: 4% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Dyspepsia (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-dyspepsia-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-dyspepsia-obesity')">table 7</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Dyspepsia (Obesity)</span>, eructation (5%), flatulence (adolescents and adults: 3% to 4%), gastroesophageal reflux disease (5%), increased serum lipase (adolescents and adults: 2% to 5%), upper abdominal pain (5%), viral gastroenteritis (3%), xerostomia (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Abdominal Pain (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-abdominal-pain-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Abdominal Pain (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Cholelithiasis (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-cholelithiasis-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Cholelithiasis (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Dyspepsia (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-dyspepsia-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Dyspepsia (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,384</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,941</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children ≥12 years and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (2%), depression (adolescents: 4%), dizziness (adolescents and adults: 7% to 10%), fatigue (adolescents and adults: 5% to 8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (adolescents: 3%), limb pain (adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (adolescents: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: First degree atrioventricular block, left bundle branch block, right bundle branch block, systolic hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Papillary thyroid carcinoma</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Cholecystitis<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Cholecystitis (Obesity) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-cholecystitis-obesity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-cholecystitis-obesity')">table 8</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Cholecystitis (Obesity)</span>, malignant neoplasm of colon or rectum, pancreatitis (including chronic pancreatitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24702687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24702687'])">Ref</a></span>)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Cholecystitis (Obesity)" frame="border" id="lexi-content-liraglutide-adverse-reaction-cholecystitis-obesity" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Cholecystitis (Obesity)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Obesity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Malignant neoplasm of breast</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Type 2 diabetes mellitus:</b> Incidence reported with adult patients in monotherapy trials unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic<b>: </b>Hypoglycemia (children and adolescents: 21%; literature suggests an increased risk of hypoglycemia in pediatric patients regardless of concomitant use of other antidiabetic agents [Danne 2017; Mastrandea 2019; Tamborlane 2019])</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal<b>: </b>Diarrhea (10% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Diarrhea (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-diarrhea-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-diarrhea-diabetes')">table 9</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Diarrhea (Diabetes)</span>, nausea (18% to 20%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Nausea (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-nausea-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-nausea-diabetes')">table 10</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Nausea (Diabetes)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Diarrhea (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-diarrhea-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Diarrhea (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,024</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Nausea (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-nausea-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Nausea (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,024</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system<b>: </b>Headache (10% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (5%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Constipation (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-constipation-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-constipation-diabetes')">table 11</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Constipation (Diabetes)</span>, gallbladder disease (3%; including cholecystitis [1%] and cholelithiasis [2%] requiring cholecystectomy)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Cholecystitis (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-cholecystitis-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-cholecystitis-diabetes')">table 12</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Cholecystitis (Diabetes)</span>
<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Cholelithiasis (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-cholelithiasis-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-cholelithiasis-diabetes')">table 13</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Cholelithiasis (Diabetes)</span>, dyspepsia (4% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Dyspepsia (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-dyspepsia-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-dyspepsia-diabetes')">table 14</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Dyspepsia (Diabetes)</span>, increased amylase (1%), increased serum lipase (8%), vomiting (6% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Liraglutide: Adverse Reaction: Vomiting (Diabetes) table link" class="lexi-table-link" data-table-id="lexi-content-liraglutide-adverse-reaction-vomiting-diabetes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-liraglutide-adverse-reaction-vomiting-diabetes')">table 15</a>)</span><span class="table-link" style="display:none;">Liraglutide: Adverse Reaction: Vomiting (Diabetes)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Cholecystitis (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-cholecystitis-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Cholecystitis (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,668</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,672</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Cholelithiasis (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-cholelithiasis-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Cholelithiasis (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,668</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,672</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Constipation (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-constipation-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Constipation (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,024</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Dyspepsia (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-dyspepsia-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: </b>
<b>Dyspepsia</b>
<b> (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,024</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Liraglutide: Adverse Reaction: Vomiting (Diabetes)" frame="border" id="lexi-content-liraglutide-adverse-reaction-vomiting-diabetes" rules="all">
<caption style="text-align:center;">
<b>Liraglutide: Adverse Reaction: Vomiting (Diabetes)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Liraglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,024</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Diabetes</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">661</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hyperbilirubinemia (monotherapy and combination trials: 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Antibody development (≤9%; neutralizing antibodies: 2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site reaction (including erythema, rash) (monotherapy and combination trials: 2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Back pain (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasopharyngitis (9% to 10%), upper respiratory tract infection (7%)</p>
<p style="text-indent:0em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: Papillary thyroid carcinoma</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Psoriasiform eruption (Bovijn 2019), pustular rash (exanthematous pustulosis) (Cogen 2019), vesicular eruption (vesiculopustular dermatosis) (Besemer 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amyloidosis (cutaneous), medullary thyroid carcinoma, thyroid disease (C-cell hyperplasia)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (including hemorrhagic pancreatitis and necrotizing pancreatitis) (Dolan 2020, FDA 2013), biliary tract disease (He 2022), cholangitis (Faillie 2016), cholestasis (Faillie 2016; Pi-Sunyer 2015), delayed gastric emptying (gastroparesis) (Almustanyir 2020), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancreatic adenocarcinoma (Alves 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatotoxicity (Parvataneni 2021), hepatitis (Kern 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (FDA 2017), angioedema (FDA 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Gariani 2014), renal tubular necrosis (Kaakeh 2012)</p></div>
<div class="block coi drugH1Div" id="F9844232"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity (eg, anaphylactic reactions, angioedema) to liraglutide or any component of the formulation; history of or family history of MTC; patients with multiple endocrine neoplasia syndrome type 2 (MEN2); pregnancy (Saxenda).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to liraglutide or any component of the formulation; pregnancy (Victoza); breastfeeding.</p></div>
<div class="block war drugH1Div" id="F9844233"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Use may be associated with the development of anti-liraglutide antibodies. Antibody formation was not associated with a loss of efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Increased resting heart rate has been observed in placebo-controlled trials; monitoring is recommended. When used for chronic weight management, the manufacturer recommends discontinuation in patients who experience a sustained increase in resting heart rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Suicidal behavior, with one case of attempted suicide, has been reported in patients treated for obesity; monitor for new or worsening depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. Discontinue use if suicidal thoughts or behaviors occur. Avoid use in patients with history of suicidal attempts or active suicidal ideation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">– Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastroparesis: Slows gastric emptying; has not been studied in patients with preexisting gastroparesis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; limited experience.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; limited data are available in this population (Mann 2018; Mann 2020). A single-dose pharmacokinetic study suggests that liraglutide pharmacokinetics are unaffected by kidney dysfunction (Jacobsen 2009). Post hoc analyses of the LEADER trial, which included patients with type 2 diabetes at high risk for cardiovascular events, suggest equal safety and efficacy of unadjusted dosing in patients with eGFR &lt;60 mL/minute/1.73 m<sup>2 </sup>compared to patients with eGFR ≥60 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Diabetes mellitus: Victoza is not for use in patients with type 1 diabetes mellitus; not a substitute for insulin. Saxenda is not indicated for the treatment of type 2 diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Weight loss: Safety and effectiveness in combination with other products intended for weight loss have not been established.</p></div>
<div class="block foc drugH1Div" id="F9844294"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Saxenda: 18 mg/3 mL (3 mL) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Victoza: 18 mg/3 mL (3 mL) [contains phenol, propylene glycol]</p></div>
<div class="block geq drugH1Div" id="F9844224"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322813"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Saxenda Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg/3 mL (per mL): $107.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Victoza Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg/3 mL (per mL): $108.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871144"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Saxenda: 18 mg/3 mL (3 mL) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Victoza: 6 mg/mL (3 mL) [contains phenol, propylene glycol]</p></div>
<div class="block adm drugH1Div" id="F9844289"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Inject SUBQ in the upper arm, thigh, or abdomen; rotate injection sites within the same body region. Do not inject IV or IM. Administer without regard to meals or time of day. Change needle with each administration. Use only if clear, colorless, and free of particulate matter. Do not share pens between patients even if needle is changed. If using concomitantly with insulin, administer as separate injections (do <b>not</b> mix); may inject in the same body region as insulin, but not adjacent to one another. For each new prefilled pen (Saxenda or Victoza), prime the needle before the first injection by turning the dose selector to the flow check symbol and injecting into the air (priming is not required for subsequent injections). Use a new needle for each injection. Once injected, continue to depress the button until the dial has returned to 0 <b>and</b> for an additional 6 seconds. Then, remove the needle.</p></div>
<div class="block admp drugH1Div" id="F53339051"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SUBQ: Inject SUBQ in the upper arm, thigh, or abdomen; rotate injection sites within the same body region. Do not inject IV or IM. Administer any time of day without regard to meals. If using concomitantly with insulin, administer as separate injections (do not mix in same syringe); may inject in the same body region, but not adjacent to one another. Change needle with each administration; do not share pens between patients even if needle is changed. In pediatric obesity trials, doses were administered at 8 AM (± 2 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27979579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27979579'])">Ref</a></span>). For each new prefilled pen (Saxenda or Victoza), prime the needle before the first injection by turning the dose selector to the flow check symbol and injecting into the air (priming is not required for subsequent injections). Use a new needle for each injection. Once injected, continue to depress the button until the dial has returned to 0 and for an additional 6 seconds. Then, remove the needle.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Diabetes mellitus, type 2: Victoza: If a dose is missed, the once-daily regimen can be resumed with the next scheduled dose (an extra dose or an increase in the next dose should not be attempted); if &gt;3 days have passed since the last liraglutide dose, reinitiate therapy at initial doses to avoid GI symptoms and titrate according to prescriber discretion (see "Dosing: Pediatric").</p>
<p style="text-indent:-2em;margin-left:4em;">Weight management, chronic: Saxenda: If ≤3 days of therapy are missed, resume once-daily dosing with the next prescribed dose; do not administer extra or doubled doses. If &gt;3 days of therapy are missed, therapy should be restarted at the initial dose (see "Dosing: Pediatric") and retitrated to avoid GI symptoms.</p></div>
<div class="block hazard drugH1Div" id="F49132786"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Prepared/prefilled syringes may be excluded from some hazardous drug handling requirements; assess risk to determine appropriate containment strategy (USP-NF 2018). Refer to institution-specific handling policies and procedures.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. The National Institute for Occupational Safety and Health recommends double gloving and a protective gown during subcutaneous administration from a prepared/prefilled syringe (NIOSH 2016).</p></div>
<div class="block meg drugH1Div" id="F9844182"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Saxenda: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F206321s016lbl.pdf%23page%3D30&amp;token=dVJ6LnoiPZlVHwiTIU3v%2FsdfrfMmct3fAzW76%2FfPFoUINek3SunhPdPglp8yNmO%2BySPatrztxiGvJ84nT1D7FA3gNH%2FFGSauoCBrFLfsFt4DpZSktpgywyrV%2BG7KO6ZM&amp;TOPIC_ID=9522" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Victoza: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022341s039lbl.pdf%23page%3D31&amp;token=r8GR8Qh%2FYdu3xD%2FBaaR4y1c8y4Xw41L1i0J6jA%2FHAO6rfjRSeZmZ1tk9bRveLtZmRZ3H33uwLJu5QXf4Xd0%2B9jDTcmMtLTyr3X0%2FvazwwuSRBcs0s5LyZpnDMPkVFHur&amp;TOPIC_ID=9522" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F9844228"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment</b> (Victoza): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus; risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic</b> (Saxenda): As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of ≥30 kg/m<sup>2</sup> (obesity) or ≥27 kg/m<sup>2</sup> (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia) and pediatric patients ≥12 years of age with body weight &gt;60 kg and an initial BMI corresponding to ≥30 kg/m<sup>2</sup> for adults (obesity) by international cut-offs (Cole Criteria).</p></div>
<div class="block mst drugH1Div" id="F9844181"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if pens are shared among multiple patients. Steps should be taken to prohibit sharing of pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299609"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9922622"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: Liraglutide may enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Liraglutide may enhance the hypoglycemic effect of Insulins.  Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides.  Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May enhance the hypoglycemic effect of Liraglutide. Liraglutide may diminish the therapeutic effect of Propranolol. Specifically, the heart rate lowering effect of propranolol may be diminished. Propranolol may diminish the therapeutic effect of Liraglutide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092129"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Obesity increases the risk of infertility. Optimal weight control prior to conception improves pregnancy outcomes. However, medications for weight loss are not recommended prior to pregnancy due to safety issues and adverse events. Weight loss medications should be discontinued prior to conception (ACOG 2021; Wharton 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2021; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F9844844"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">An increased risk of adverse maternal and fetal events is associated with obesity. However, moderate gestational weight gain based on pre-pregnancy BMI is required for positive fetal outcomes in all pregnancies, including patients who are overweight or obese. Therefore, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021; Wharton 2020). Use of liraglutide for chronic weight management is contraindicated in pregnant patients (lack of potential benefit and possible fetal harm).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2021; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than liraglutide are currently recommended to treat diabetes during pregnancy (ADA 2021).</p></div>
<div class="block brc drugH1Div" id="F20548037"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if liraglutide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Due to safety concerns, medications for weight loss therapy are not recommended for patients who are breastfeeding (Wharton 2020).</p></div>
<div class="block dic drugH1Div" id="F9844285"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. </p></div>
<div class="block mop drugH1Div" id="F9844291"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma glucose; renal function; signs/symptoms of pancreatitis (eg, persistent severe abdominal pain, which may radiate to the back and which may or may not be accompanied by vomiting); triglycerides; signs/symptoms of gallbladder disease; gallbladder studies and further clinical assessment are indicated if cholelithiasis is suspected; emergence of worsening depression, suicidal thoughts/behavior, changes in behavior; heart rate; body weight (at week 16 when used for chronic weight management).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F9844246"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant <i>adults (AACE [Samson 2023]; ADA 2023):</i></i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023)<i>:</i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Children and adolescents: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial glucose: 70 to 130 mg/dL (SI: 3.9 to 7.2 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Postprandial glucose: 90 to 180 mg/dL (SI: 5 to 10 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime/overnight glucose: 80 to 140 mg/dL (SI: 4.4 to 7.8 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2023; ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Surgical patients (ISPAD [Jefferies 2018]):</p>
<p style="text-indent:-2em;margin-left:8em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:8em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F9844244"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Liraglutide is a long acting analog of human glucagon-like peptide-1 (GLP-1) (an incretin hormone) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Liraglutide administration results in decreases in hemoglobin A<sub>1c</sub> by approximately 1%.</p></div>
<div class="block phk drugH1Div" id="F9844247"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetic data in type 2 diabetes mellitus pediatric patients (10 to 17 years) is similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: SUBQ: ~13 L; IV: 0.07 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Endogenously metabolized by dipeptidyl peptidase 4 (DPP-4) and endogenous endopeptidases (Croom 2009); metabolism occurs slower than that seen with native GLP-1.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: ~55%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: ~13 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SUBQ: 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (6%, as metabolites); feces (5%, as metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51153964"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Exposure decreases with an increase in baseline body weight; however, the 1.2 mg and 1.8 mg daily doses of liraglutide provided adequate systemic exposures over the body weight range of 40 to 160 kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390244"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Saxenda</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Liraglutido | Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Saxenda</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Victoza</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Saxenda | Victoza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2018:84-103.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33403167">
<a name="33403167"></a>Almustanyir S, Alhabeeb H, AlHusseini N, Al Thow M. Gastroparesis with the initiation of liraglutide: a case report. <i>Cureus</i>. 2020;12(11):e11735. doi:10.7759/cureus.11735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/33403167/pubmed" id="33403167" target="_blank">33403167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010561">
<a name="23010561"></a>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <i>Diabetes Res Clin Pract</i>. 2012;98(2):271-284. doi:10.1016/j.diabres.2012.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/23010561/pubmed" id="23010561" target="_blank">23010561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011890">
<a name="34011890"></a>American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 230: Obesity in pregnancy. <i>Obstet Gynecol</i>. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/34011890/pubmed" id="34011890" target="_blank">34011890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964865">
<a name="34964865"></a>American Diabetes Association (ADA). 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. <i>Diabetes Care</i>. 2022a;45(suppl 1):S208-S231. doi:10.2337/dc22-S014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/34964865/pubmed" id="34964865" target="_blank">34964865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964868">
<a name="34964868"></a>American Diabetes Association (ADA). 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. <i>Diabetes Care</i>. 2022b;45(suppl 1):S83-S96. doi:10.2337/dc22-S006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/34964868/pubmed" id="34964868" target="_blank">34964868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bailie.1">
<a name="Bailie.1"></a>Bailie GR, Mason NA. <i>Bailie and Mason’s 2020 Dialysis of Drugs</i>. Renal Pharmacy Consultants LLC; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22727533">
<a name="22727533"></a>Besemer F, Verschoor AJ, Diamant M, Hoogma RP. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide? <i>J Diabetes Complications</i>. 2012;26(5):458-459. doi:10.1016/j.jdiacomp.2012.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/22727533/pubmed" id="22727533" target="_blank">22727533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20203154">
<a name="20203154"></a>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation [published correction appears in <i>Endocrinology</i>. 2012;153(2):1000. Moerch, Ulrik [added]]. <i>Endocrinology</i>. 2010;151(4):1473-1486. doi:10.1210/en.2009-1272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/20203154/pubmed" id="20203154" target="_blank">20203154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31903972">
<a name="31903972"></a>Bovijn L, Arianayagam S, Asher R. An unusual case of a generalised cutaneous drug reaction to liraglutide. <i>Eur J Dermatol</i>. 2019;29(6):675-677. doi:10.1684/ejd.2019.3691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31903972/pubmed" id="31903972" target="_blank">31903972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21450987">
<a name="21450987"></a>Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.<i> J Clin Endocrinol Metab</i>. 2011;96(6):1695-1702. doi:10.1210/jc.2010-2822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/21450987/pubmed" id="21450987" target="_blank">21450987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDA.1">
<a name="CDA.1"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. <i>Can J Diabetes. </i>2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301438">
<a name="32301438"></a>Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report [published online ahead of print, 2020 Apr 17]. <i>J Investig Allergol Clin Immunol</i>. 2020;0. doi:10.18176/jiaci.0521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32301438/pubmed" id="32301438" target="_blank">32301438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31389984">
<a name="31389984"></a>Cogen AL, Desai K, Elder D, Rosenbach M. Acute photodistributed exanthematous pustulosis associated with liraglutide treatment [published online ahead of print, 2019 Aug 7]. <i>JAMA Dermatol</i>. 2019;10.1001/jamadermatol.2019.1893. doi:10.1001/jamadermatol.2019.1893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31389984/pubmed" id="31389984" target="_blank">31389984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747013">
<a name="19747013"></a>Croom KF, McCormack PL. Liraglutide: A Review of Its Use in Type 2 Diabetes Mellitus. <i>Drugs.</i> 2009;69(14):1985-2004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/19747013/pubmed" id="19747013" target="_blank">19747013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27979579">
<a name="27979579"></a>Danne T, Biester T, Kapitzke K, et al. Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years. <i>J Pediatr</i>. 2017;181:146-153.e3. doi:10.1016/j.jpeds.2016.10.076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27979579/pubmed" id="27979579" target="_blank">27979579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30497881">
<a name="30497881"></a>Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2018;72(24):3200-3223. doi:10.1016/j.jacc.2018.09.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30497881/pubmed" id="30497881" target="_blank">30497881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>De Bock M, Codner E, Craig ME, et al. ISPAD clinical practice consensus guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32607380">
<a name="32607380"></a>Dolan RD, Bazarbashi AN, Lo A, Smith BN. Liraglutide-induced hemorrhagic pancreatitis in a nondiabetic patient. <i>ACG Case Rep J</i>. 2020;7(5):e00380. doi:10.14309/crj.0000000000000380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32607380/pubmed" id="32607380" target="_blank">32607380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24571751">
<a name="24571751"></a>Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment [published correction appears in <i>N Engl J Med</i>. 2014 Jun 5;370(23):2253]. <i>N Engl J Med</i>. 2014;370(9):794-797. doi:10.1056/NEJMp1314078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/24571751/pubmed" id="24571751" target="_blank">24571751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21334333">
<a name="21334333"></a>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. <i>Gastroenterology</i>. 2011;141(1):150-156. doi:10.1053/j.gastro.2011.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/21334333/pubmed" id="21334333" target="_blank">21334333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27478902">
<a name="27478902"></a>Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. <i>JAMA Intern Med</i>. 2016;176(10):1474-1481. doi:10.1001/jamainternmed.2016.1531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27478902/pubmed" id="27478902" target="_blank">27478902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2013">
<a name="FDA.2013"></a>FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Published March 14, 2013. Accessed September 14, 2020. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2017">
<a name="FDA.2017"></a>FDA Briefing Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC). Published June 20, 2017. Accessed September 14, 2020. <a href="https://www.fda.gov/media/105560/download" target="_blank">https://www.fda.gov/media/105560/download</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26177483">
<a name="26177483"></a>Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. <i>Rev Diabet Stud</i>. 2014;11(3-4):202-230. doi:10.1900/RDS.2014.11.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/26177483/pubmed" id="26177483" target="_blank">26177483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi: 10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24315766">
<a name="24315766"></a>Gariani K, de Seigneux S, Moll S. Acute interstitial nephritis after treatment with liraglutide. <i>Am J Kidney Dis</i>. 2014;63(2):347. doi:10.1053/j.ajkd.2013.10.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/24315766/pubmed" id="24315766" target="_blank">24315766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27219496">
<a name="27219496"></a>Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE obesity clinical practice guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. <i>Endocr Pract</i>. 2016;22(suppl 3):1-203. doi:10.4158/EP161365.GL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27219496/pubmed" id="27219496" target="_blank">27219496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24702687">
<a name="24702687"></a>Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. <i>Diabetes Obes Metab</i>. 2014;16(11):1041-1047. doi:10.1111/dom.12297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/24702687/pubmed" id="24702687" target="_blank">24702687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36273831">
<a name="36273831"></a>Grunvald E, Shah R, Hernaez R, et al; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. <i>Gastroenterology</i>. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/36273831/pubmed" id="36273831" target="_blank">36273831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344001">
<a name="35344001"></a>He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. <i>JAMA Intern Med</i>. 2022;e220338. doi:10.1001/jamainternmed.2022.0338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/35344001/pubmed" id="35344001" target="_blank">35344001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26556397">
<a name="26556397"></a>Hiramatsu T, Ozeki A, Asai K, Saka M, Hobo A, Furuta S. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. <i>Ther Apher Dial</i>. 2015;19(6):598-605. doi:10.1111/1744-9987.12319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/26556397/pubmed" id="26556397" target="_blank">26556397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27981757">
<a name="27981757"></a>Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. <i>Diabetes Obes Metab</i>. 2017;19(4):524-536. doi:10.1111/dom.12849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27981757/pubmed" id="27981757" target="_blank">27981757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26283739">
<a name="26283739"></a>Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. <i>Diabetes Care</i>. 2016;39(2):206-213. doi:10.2337/dc15-1025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/26283739/pubmed" id="26283739" target="_blank">26283739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20002084">
<a name="20002084"></a>Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. <i>Br J Clin Pharmacol</i>. 2009;68(6):898-905. doi:10.1111/j.1365-2125.2009.03536.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/20002084/pubmed" id="20002084" target="_blank">20002084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery [published correction appears in <i>Pediatr Diabetes</i>. 2019;20(1):137]. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227–236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22392833">
<a name="22392833"></a>Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. <i>Pharmacotherapy</i>. 2012;32(1):e7-e11. doi:10.1002/PHAR.1014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/22392833/pubmed" id="22392833" target="_blank">22392833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733687">
<a name="24733687"></a>Kern E, VanWagner LB, Yang GY, Rinella ME. Liraglutide-induced autoimmune hepatitis. <i>JAMA Intern Med</i>. 2014;174(6):984-987. doi:10.1001/jamainternmed.2014.674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/24733687/pubmed" id="24733687" target="_blank">24733687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27883260">
<a name="27883260"></a>Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. <i>Diabetes Obes Metab</i>. 2017;19(3):401-411. doi:10.1111/dom.12833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27883260/pubmed" id="27883260" target="_blank">27883260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725635">
<a name="25725635"></a>Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. <i>Aging Clin Exp Res</i>. 2015;27(5):751-753. doi:10.1007/s40520-015-0335-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/25725635/pubmed" id="25725635" target="_blank">25725635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30566006">
<a name="30566006"></a>Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Circulation</i>. 2018;138(25):2908-2918. doi:10.1161/CIRCULATIONAHA.118.036418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30566006/pubmed" id="30566006" target="_blank">30566006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32132141">
<a name="32132141"></a>Mann JFE, Fonseca VA, Poulter NR, et al. Safety of liraglutide in type 2 diabetes and chronic kidney disease. <i>Clin J Am Soc Nephrol</i>. 2020;15(4):465-473. doi:10.2215/CJN.11881019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32132141/pubmed" id="32132141" target="_blank">32132141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27295427">
<a name="27295427"></a>Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes.<i> N Engl J Med</i>. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27295427/pubmed" id="27295427" target="_blank">27295427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18829977">
<a name="18829977"></a>Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i>. 2009;58(7):990-997. doi:10.1136/gut.2008.150870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/18829977/pubmed" id="18829977" target="_blank">18829977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631146">
<a name="17631146"></a>Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. <i>Gastroenterology</i>. 2007;133(1):244-255. doi:10.1053/j.gastro.2007.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/17631146/pubmed" id="17631146" target="_blank">17631146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27709794">
<a name="27709794"></a>Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. <i>Diabetes Obes Metab</i>. 2017;19(2):200-207. doi:10.1111/dom.12802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/27709794/pubmed" id="27709794" target="_blank">27709794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399438">
<a name="31399438"></a>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. <i>Diabetes Care</i>. 2019;42(10):1912-1920. doi:10.2337/dc19-0415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31399438/pubmed" id="31399438" target="_blank">31399438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neel.2019">
<a name="Neel.2019"></a>Neel NF. Liraglutide-induced injection site reaction. <i>Journal of Dermatology &amp; Dermatologic Surgery</i>. 2019;23(2):97-98.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30350785">
<a name="30350785"></a>Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira Barbosa M. Anaphylaxis to long-acting release exenatide. <i>J Investig Allergol Clin Immunol</i>. 2018;28(5):332-334. doi:10.18176/jiaci.0274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30350785/pubmed" id="30350785" target="_blank">30350785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25526642">
<a name="25526642"></a>Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. <i>PLoS One</i>. 2014;9(12):e113468. doi:10.1371/journal.pone.0113468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/25526642/pubmed" id="25526642" target="_blank">25526642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34471551">
<a name="34471551"></a>Parvataneni S, Ramachandran R, Then E, Grantham T, Gaduputi V. An exceedingly rare case of liraglutide-induced liver injury. <i>Case Rep Gastrointest Med</i>. 2021;2021:6306149. doi:10.1155/2021/6306149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/34471551/pubmed" id="34471551" target="_blank">34471551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439386">
<a name="25439386"></a>Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. A case report of allergy to exenatide. <i>J Allergy Clin Immunol Pract</i>. 2014;2(6):822-823. doi:10.1016/j.jaip.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/25439386/pubmed" id="25439386" target="_blank">25439386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26132939">
<a name="26132939"></a>Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. <i>N Engl J Med</i>. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/26132939/pubmed" id="26132939" target="_blank">26132939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31806579">
<a name="31806579"></a>Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. <i>Lancet Diabetes Endocrinol</i>. 2020;8(1):13-14. doi:10.1016/S2213-8587(19)30382-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31806579/pubmed" id="31806579" target="_blank">31806579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saxenda.1">
<a name="Saxenda.1"></a>Saxenda (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saxenda.1">
<a name="Saxenda.1"></a>Saxenda (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saxenda.2">
<a name="Saxenda.2"></a>Saxenda (liraglutide) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes.</i> 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31296642">
<a name="31296642"></a>Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. <i>Diabetes Care</i>. 2019;42(9):e141-e142. doi:10.2337/dc19-0720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31296642/pubmed" id="31296642" target="_blank">31296642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975753">
<a name="21975753"></a>Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. <i>Cochrane Database Syst Rev</i>. 2011;2011(10):CD006423. Published 2011 Oct 5. doi:10.1002/14651858.CD006423.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/21975753/pubmed" id="21975753" target="_blank">21975753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23440284">
<a name="23440284"></a>Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. <i>JAMA Intern Med</i>. 2013;173(7):534-539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/23440284/pubmed" id="23440284" target="_blank">23440284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30677262">
<a name="30677262"></a>Srivastava G, Fox CK, Kelly AS, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. <i>Obesity (Silver Spring)</i>. 2019;27(2):190-204. doi:10.1002/oby.22385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/30677262/pubmed" id="30677262" target="_blank">30677262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steveling.2014">
<a name="Steveling.2014"></a>Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide.<i> Journal of Pharmacy Technology</i>. 2014;30(5):182-186.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25375397">
<a name="25375397"></a>Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.<i> Diabetes Technol Ther</i>. 2015;17(1):35-42. doi:10.1089/dia.2014.0188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/25375397/pubmed" id="25375397" target="_blank">25375397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31034184">
<a name="31034184"></a>Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al; Ellipse Trial Investigators. Liraglutide in children and adolescents with type 2 diabetes. <i>N Engl J Med</i>. 2019;381(7):637-646. doi:10.1056/NEJMoa1903822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/31034184/pubmed" id="31034184" target="_blank">31034184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25633664">
<a name="25633664"></a>Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. <i>Diabetes Care</i>. 2015;38(6):1089-1098. doi:10.2337/dc13-2983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/25633664/pubmed" id="25633664" target="_blank">25633664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Victoza.1">
<a name="Victoza.1"></a>Victoza (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Victoza.2">
<a name="Victoza.2"></a>Victoza (liraglutide) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32753461">
<a name="32753461"></a>Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. <i>CMAJ</i>. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/32753461/pubmed" id="32753461" target="_blank">32753461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Initial management of blood glucose in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23622135">
<a name="23622135"></a>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. <i>Gastroenterology</i>. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liraglutide-drug-information/abstract-text/23622135/pubmed" id="23622135" target="_blank">23622135</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9522 Version 322.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
